A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond

Lalita Prasad-Reddy, Diana Isaacs, Lalita Prasad-Reddy, Diana Isaacs

Abstract

The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight gain. Glucagon-like peptide-1 (GLP-1) receptor agonists represent a unique approach to the treatment of diabetes, with benefits extending outside glucose control, including positive effects on weight, blood pressure, cholesterol levels, and beta-cell function. They mimic the effects of the incretin hormone GLP-1, which is released from the intestine in response to food intake. Their effects include increasing insulin secretion, decreasing glucagon release, increasing satiety, and slowing gastric emptying. There are currently four approved GLP-1 receptor agonists in the United States: exenatide, liraglutide, albiglutide, and dulaglutide. A fifth agent, lixisenatide, is available in Europe. There are important pharmacodynamic, pharmacokinetic, and clinical differences of each agent. The most common adverse effects seen with GLP-1 therapy include nausea, vomiting, and injection-site reactions. Other warnings and precautions include pancreatitis and thyroid cell carcinomas. GLP-1 receptor agonists are an innovative and effective option to improve blood glucose control, with other potential benefits of preserving beta-cell function, weight loss, and increasing insulin sensitivity. Once-weekly formulations may also improve patient adherence. Overall, these are effective agents for patients with type 2 diabetes, who are either uncontrolled on metformin or intolerant to metformin.

Keywords: albiglutide; beta cell; dulaglutide; exenatide; glucagon-like peptide-1 receptor agonist; insulin sensitivity; liraglutide; subcutaneous; type 2 diabetes mellitus; weight loss.

References

    1. International Diabetes Federation . IDF diabetes atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2014. Update. Available at: [Last accessed: May 2nd, 2015].
    1. American Diabetes Association Standards of medical care in diabetes: 2015. Diabetes Care. 2015;38(Suppl 1):S1–99.
    1. Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(11):1140–49. .
    1. Donath MY, Ehses JA, Maedler K, Schumann D, Ellingsgaard H, Eppler E, Reineke M. Mechanisms of beta-cell death in type 2 diabetes. Diabetes. 2005;54(Suppl 2):S108–13. .
    1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–57. .
    1. Drucker DJ, Buse JB, Taylor Kendall DM, Trautmann M, Zhaung D, Porter L. Duration-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, openlabel, non-inferiority study. Lancet. 2008;372(9645):1240–50. .
    1. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6) Lancet. 2009;374(9683):39–47. .
    1. DeFronzo R. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95. .
    1. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717–23. .
    1. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929–40. .
    1. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187–218. .
    1. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78–107amide) on hepatic glucose production in healthy man. Metabolism. 1994;43(1):104–8.
    1. Mentis N, Vardarli I, Köthe LD, Holst JJ, Deacon CF, Theodorakis M, Meier JJ, Nauck MA. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes. 2011;60(4):1270–6. .
    1. Gupta V. Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab. 2013;17(3):413–21. .
    1. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824–30. .
    1. Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68(5):557–67. .
    1. Byetta package insert. Available at . [Last Accessed: May 2nd, 2015]
    1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705. .
    1. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–100. .
    1. Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, Basson BR, Festa A, Kiljański J, Sapin H, Trautmann M, Schernthaner G. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012;379(9833):2270–80. .
    1. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008 Oct;24(10):2943–52. .
    1. Victoza package insert. Available at . [Last accessed: April 25th, 2015].
    1. Madsen K, Knudsen LB, Nielsen PF, Thogersen H, Wilken M, Johansen NL. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem. 2007;50:6126–32. .
    1. Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J. Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010 Jun;33(6):1300–3. .
    1. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R. Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009 Oct;52(10):2046–55. .
    1. Bydureon package insert. Available at . [Last accessed: April 23rd, 2015].
    1. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13(2):144–49. .
    1. Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013 Jan 12;381(9861):117–24. .
    1. Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010 Jun 26;375(9733):2234–43. .
    1. Tanzeum package insert. Available at [Last accessed: May 3rd, 2015].
    1. Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC, Gutierrez M, Stewart MW. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009 May;11(5):498–505. .
    1. Reinhardt R, Nauck MA, Stewart M, Perkins C, Jones-Leone A, Yang F, Perry C, Rendell M. Harmony 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise [abstract] Available from: . [Last Accessed: May 7th, 2015]
    1. Weissman PN, Carr MC, Ye J, Cirkel DT, Stewart M, Perry C, Pratley R. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014 Dec;57(12):2475–84. .
    1. Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J. HARMONY 7 Study Group. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014 Apr;2(4):289–97. .
    1. Trulicity package insert. Available at . [Last accessed: May 3rd, 2015].
    1. Barrington P, Chien JY, Showalter HD, Schneck K, Cui S, Tibaldi F, Ellis B, Hardy TA. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:426–33. .
    1. Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, Kuhstoss D, Lakshmanan M. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial(AWARD-1) Diabetes Care. 2014;37:2159–67. .
    1. Giorgino F, Benroubi M, Sun J, Zimmermann A, Pechtner V. Efficacy and safety of once-weekly dulaglutide vs. insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2) Diabetologia. 2014;57(Suppl 1):A38. .
    1. Dungan K, Povedano S, Forst T, Gonzalez J, Atisso C, Sealls W, Fahrbach J. Once-weekly dulaglutide versus once-daily liraglutide in metformin treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349–57. .
    1. Lixisenatide summary of product characteristics. Available at . [Last accessed: May 2nd, 2015].
    1. Kapitza C, Forst T, Coester H, Poitiers F, Ruus P, Hincelin-Méry A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab. 2013 Jul;15(7):642–649. .
    1. Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res. 2012;9(2):95–108. .
    1. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33(2):428–33. .
    1. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies. Diabetes Care. 2011;34:90–5. .
    1. Saraiva FK, Sposito A. Cardiovascular effects of glucagon-like peptide-1 (GLP-1) receptor agonists. Cardiovasc Diabet. 2014;13:142. .
    1. Bergenstal RM, Wysham C, Macconell L, Mally J, Walsh B, Ping Y, Wilhelm K, Malone J, Porter LE. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–9. .
    1. Visboll T, Christensen M, Junker A, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: a systematic review and meta-analysis of randomized controlled trials. BMJ. 2012;344:d7771. .
    1. Saxenda package insert. Available at . [Last accessed: May 4th, 2015].
    1. Astrup A, Rossner S, Van Gaal L, Risanen A, Niskanen L, Hakim MA, Madsen J, Rasussen MF, Jean M. Effects of liraglutide in the treatment of obesity: a randomised double-blind, placebo-controlled study. Lancet. 2009;374(9071):1606–16. .
    1. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S. LEAD-1 SU Study Group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulfonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabet Med. 2009;26:268–78. .
    1. Nauck M, Frid A, Hermansen KS, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR, LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90. .
    1. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B, LEAD-3 (Mono) Study Group Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–81. .
    1. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, LEAD-4 Study Investigators Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) Diabetes Care. 2009;32:1224–30. .
    1. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R, Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55. .
    1. Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocr Metab. 2011;96:1301–10. .
    1. Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011 Jun;28(6):705–14. .
    1. Ahren B, Johnson SL, Steward M, Cirkel DT, Yang F, Perry C, Feinglos MN. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;7(8):2141–8. .
    1. Russel-Jones D, Cuddihy R, Hanefeld M, Kumar A, Gonzalez JG, Chan M, Wolka A, Boardman M, Duration-4 Study Group Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as mootherapy in drug-naïve patients with type 2 diabetes (DURATION-4) Diabetes Care. 2012;35(2):252–58. .
    1. Stewart M, Home P, Yang F, Perry C, Carr MC. 52-Week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with T2D: HARMONY 5 study. Diabetologia. 2013;56(Suppl 1):S361.
    1. Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, Reinhardt RR, Bode BW. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014 Dec;16(12):1257–64. .
    1. Rosenstock J, Fonseca VA, Gross JL, Ratner RE, Ahrén B, Chow FC, Yang F, Miller D, Johnson SL, Stewart MW, Leiter LA, Harmony 6 Study Group Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014 Aug;37(8):2317–25. .
    1. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta cell function. Am Fam Physician. 2004;70(3):489–500.
    1. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists. A review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279–84. .
    1. Cefalue WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC. Beyond metformin: safety consideration in the decision making process for selecting a second medication for type 2 diabetes management. Reflections from a diabetes care editors’ expert forum. Diabetes Care. 2014;37:2647–59. .
    1. Edwards KL, Minze MG. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes. Core Evid. 2015;10:11–21. .
    1. Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, Zhang Y, Ji L, Zhan S. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res. 2015;2015:157201. .
    1. AACE 2015 guidelines type 2 diabetes. Available at . [Last accessed: May 5th, 2015].
    1. Rosenstock J, Balas B, Charbonnel B, Bolli G, Boldrin M, Ratner R, Balena R. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes. The T-Emerge 2 trial. Diabetes Care. 2013;36(3):498–504. .
    1. United States Food and Drug Administration . Guidance for industry diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: US Department of Health and Human Services; 2008. Available at: . [Last accessed: May 3rd, 2015].
    1. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:38–47. .
    1. Marso SP, Lindsey JB, Stolker JM, House JA, Martinez Ravn G, Kennedy KF, Jensen TM, Buse JB. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8:237–40. .
    1. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerd BJ, Sheri L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22. .
    1. Tibble CA, Cavaiola TS, Henry RR. Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes. A review of current literature. Expert Rev Endocrinol Metab. 2013;8(2):247–59.
    1. Fineman MS, Mace KF, Diamant M, Darsow T, Circione BB, Booker Porter TK, Kinniger LA, Trautmann ME. Clinical relevance of anti-exenatide antibodies: safety, efficacy, and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012 Jun;14(6):546–54. .
    1. Fillippatos TD, Elisaf MS. Effects of glucagon-like peptide 1 receptor agonists on renal function. World J Diabetes. 2013 Oct 15;4(5):190–201. .
    1. Information for Healthcare Professionals: reports of Altered Kidney Function in patients using Exenatide (Marketed as Byetta) 11/2/2009. Available at: . [Last accessed: May 3rd, 2015].
    1. Leiter LA, Carr MC, Steward M, Jones-Leone A, Scott R, Yang F, Hadelsman Y. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37(10):2723–30. .
    1. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228–34. .
    1. Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet. 2014;2(11):855–93. .
    1. Buse JB, Vilsboll T, Thurman J, Blevin TC, Langbakke IH, Bottcher SG, Rodbard HW. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDEgLira) Diabetes Care. 2014;37(11):2926–33. .
    1. Trujillo J, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014;48(11):1494–1501. .

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다